Dexrazoxane for reducing anthracycline-related cardiotoxicity in children with cancer: An update of the evidence

Steven E Lipshultz, Vivian I. Franco, Stephen E. Sallan, Peter C. Adamson, Rudolf K. Steiner, Sandra M. Swain, Joseph Gligorov, Giorgio Minotti

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Advances in treating childhood cancers over the past 40. years have more than doubled 5-year survival rates. More effective use of chemotherapeutic agents has been key to this success. However, the increase has come at a price: chronic conditions are significantly more prevalent in long-term survivors of childhood cancer than they are in the general population, and managing these survivors can be challenging. In patients receiving anthracyclines, cardiotoxicity is the leading cause of morbidity and mortality after relapse and second malignancies. More than 50% of patients exposed to anthracyclines exhibit some form of cardiac dysfunction within 20. years after completing chemotherapy, and about 5% develop heart failure. These conditions greatly reduce the quality of life of the individual and also consume substantial amounts of healthcare resources. Dexrazoxane has been used to reduce anthracycline-related cardiotoxicity in children with cancer, but in 2011, the European Medicines Agency determined, on what it acknowledged were limited data, that dexrazoxane was contraindicated in children. Here, we review the evidence for the clinical effects of dexrazoxane in children. Studies published since 2011 have confirmed the efficacy of dexrazoxane in preventing or reducing anthracycline-related cardiotoxicity in children with cancer, and no new evidence of increased risks for recurrence of primary or second malignancies, or reductions in antitumor efficacy has been reported. As a result, we believe that dexrazoxane should be available to children with high-risk cancers to reduce the risk of cardiotoxicity associated with high-dose anthracycline treatment.

Original languageEnglish (US)
Pages (from-to)39-49
Number of pages11
JournalProgress in Pediatric Cardiology
Volume36
Issue number1-2
DOIs
StatePublished - 2014
Externally publishedYes

Fingerprint

Dexrazoxane
Anthracyclines
Second Primary Neoplasms
Neoplasms
Survivors
Recurrence
Survival Rate
Heart Failure
Quality of Life
Cardiotoxicity
Morbidity
Delivery of Health Care
Drug Therapy
Mortality
Population

Keywords

  • Anthracyclines
  • Cancer survivorship
  • Cardioprotection
  • Cardiotoxicity
  • Dexrazoxane
  • Secondary malignancies

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pediatrics, Perinatology, and Child Health

Cite this

Lipshultz, S. E., Franco, V. I., Sallan, S. E., Adamson, P. C., K. Steiner, R., Swain, S. M., ... Minotti, G. (2014). Dexrazoxane for reducing anthracycline-related cardiotoxicity in children with cancer: An update of the evidence. Progress in Pediatric Cardiology, 36(1-2), 39-49. https://doi.org/10.1016/j.ppedcard.2014.09.007

Dexrazoxane for reducing anthracycline-related cardiotoxicity in children with cancer : An update of the evidence. / Lipshultz, Steven E; Franco, Vivian I.; Sallan, Stephen E.; Adamson, Peter C.; K. Steiner, Rudolf; Swain, Sandra M.; Gligorov, Joseph; Minotti, Giorgio.

In: Progress in Pediatric Cardiology, Vol. 36, No. 1-2, 2014, p. 39-49.

Research output: Contribution to journalArticle

Lipshultz, SE, Franco, VI, Sallan, SE, Adamson, PC, K. Steiner, R, Swain, SM, Gligorov, J & Minotti, G 2014, 'Dexrazoxane for reducing anthracycline-related cardiotoxicity in children with cancer: An update of the evidence', Progress in Pediatric Cardiology, vol. 36, no. 1-2, pp. 39-49. https://doi.org/10.1016/j.ppedcard.2014.09.007
Lipshultz, Steven E ; Franco, Vivian I. ; Sallan, Stephen E. ; Adamson, Peter C. ; K. Steiner, Rudolf ; Swain, Sandra M. ; Gligorov, Joseph ; Minotti, Giorgio. / Dexrazoxane for reducing anthracycline-related cardiotoxicity in children with cancer : An update of the evidence. In: Progress in Pediatric Cardiology. 2014 ; Vol. 36, No. 1-2. pp. 39-49.
@article{6814492778bf4644a72d8cab132af582,
title = "Dexrazoxane for reducing anthracycline-related cardiotoxicity in children with cancer: An update of the evidence",
abstract = "Advances in treating childhood cancers over the past 40. years have more than doubled 5-year survival rates. More effective use of chemotherapeutic agents has been key to this success. However, the increase has come at a price: chronic conditions are significantly more prevalent in long-term survivors of childhood cancer than they are in the general population, and managing these survivors can be challenging. In patients receiving anthracyclines, cardiotoxicity is the leading cause of morbidity and mortality after relapse and second malignancies. More than 50{\%} of patients exposed to anthracyclines exhibit some form of cardiac dysfunction within 20. years after completing chemotherapy, and about 5{\%} develop heart failure. These conditions greatly reduce the quality of life of the individual and also consume substantial amounts of healthcare resources. Dexrazoxane has been used to reduce anthracycline-related cardiotoxicity in children with cancer, but in 2011, the European Medicines Agency determined, on what it acknowledged were limited data, that dexrazoxane was contraindicated in children. Here, we review the evidence for the clinical effects of dexrazoxane in children. Studies published since 2011 have confirmed the efficacy of dexrazoxane in preventing or reducing anthracycline-related cardiotoxicity in children with cancer, and no new evidence of increased risks for recurrence of primary or second malignancies, or reductions in antitumor efficacy has been reported. As a result, we believe that dexrazoxane should be available to children with high-risk cancers to reduce the risk of cardiotoxicity associated with high-dose anthracycline treatment.",
keywords = "Anthracyclines, Cancer survivorship, Cardioprotection, Cardiotoxicity, Dexrazoxane, Secondary malignancies",
author = "Lipshultz, {Steven E} and Franco, {Vivian I.} and Sallan, {Stephen E.} and Adamson, {Peter C.} and {K. Steiner}, Rudolf and Swain, {Sandra M.} and Joseph Gligorov and Giorgio Minotti",
year = "2014",
doi = "10.1016/j.ppedcard.2014.09.007",
language = "English (US)",
volume = "36",
pages = "39--49",
journal = "Progress in Pediatric Cardiology",
issn = "1058-9813",
publisher = "Elsevier Ireland Ltd",
number = "1-2",

}

TY - JOUR

T1 - Dexrazoxane for reducing anthracycline-related cardiotoxicity in children with cancer

T2 - An update of the evidence

AU - Lipshultz, Steven E

AU - Franco, Vivian I.

AU - Sallan, Stephen E.

AU - Adamson, Peter C.

AU - K. Steiner, Rudolf

AU - Swain, Sandra M.

AU - Gligorov, Joseph

AU - Minotti, Giorgio

PY - 2014

Y1 - 2014

N2 - Advances in treating childhood cancers over the past 40. years have more than doubled 5-year survival rates. More effective use of chemotherapeutic agents has been key to this success. However, the increase has come at a price: chronic conditions are significantly more prevalent in long-term survivors of childhood cancer than they are in the general population, and managing these survivors can be challenging. In patients receiving anthracyclines, cardiotoxicity is the leading cause of morbidity and mortality after relapse and second malignancies. More than 50% of patients exposed to anthracyclines exhibit some form of cardiac dysfunction within 20. years after completing chemotherapy, and about 5% develop heart failure. These conditions greatly reduce the quality of life of the individual and also consume substantial amounts of healthcare resources. Dexrazoxane has been used to reduce anthracycline-related cardiotoxicity in children with cancer, but in 2011, the European Medicines Agency determined, on what it acknowledged were limited data, that dexrazoxane was contraindicated in children. Here, we review the evidence for the clinical effects of dexrazoxane in children. Studies published since 2011 have confirmed the efficacy of dexrazoxane in preventing or reducing anthracycline-related cardiotoxicity in children with cancer, and no new evidence of increased risks for recurrence of primary or second malignancies, or reductions in antitumor efficacy has been reported. As a result, we believe that dexrazoxane should be available to children with high-risk cancers to reduce the risk of cardiotoxicity associated with high-dose anthracycline treatment.

AB - Advances in treating childhood cancers over the past 40. years have more than doubled 5-year survival rates. More effective use of chemotherapeutic agents has been key to this success. However, the increase has come at a price: chronic conditions are significantly more prevalent in long-term survivors of childhood cancer than they are in the general population, and managing these survivors can be challenging. In patients receiving anthracyclines, cardiotoxicity is the leading cause of morbidity and mortality after relapse and second malignancies. More than 50% of patients exposed to anthracyclines exhibit some form of cardiac dysfunction within 20. years after completing chemotherapy, and about 5% develop heart failure. These conditions greatly reduce the quality of life of the individual and also consume substantial amounts of healthcare resources. Dexrazoxane has been used to reduce anthracycline-related cardiotoxicity in children with cancer, but in 2011, the European Medicines Agency determined, on what it acknowledged were limited data, that dexrazoxane was contraindicated in children. Here, we review the evidence for the clinical effects of dexrazoxane in children. Studies published since 2011 have confirmed the efficacy of dexrazoxane in preventing or reducing anthracycline-related cardiotoxicity in children with cancer, and no new evidence of increased risks for recurrence of primary or second malignancies, or reductions in antitumor efficacy has been reported. As a result, we believe that dexrazoxane should be available to children with high-risk cancers to reduce the risk of cardiotoxicity associated with high-dose anthracycline treatment.

KW - Anthracyclines

KW - Cancer survivorship

KW - Cardioprotection

KW - Cardiotoxicity

KW - Dexrazoxane

KW - Secondary malignancies

UR - http://www.scopus.com/inward/record.url?scp=84921406668&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84921406668&partnerID=8YFLogxK

U2 - 10.1016/j.ppedcard.2014.09.007

DO - 10.1016/j.ppedcard.2014.09.007

M3 - Article

AN - SCOPUS:84921406668

VL - 36

SP - 39

EP - 49

JO - Progress in Pediatric Cardiology

JF - Progress in Pediatric Cardiology

SN - 1058-9813

IS - 1-2

ER -